P W Harvey

Summary

Affiliation: Covance Laboratories
Country: USA

Publications

  1. ncbi Adrenocortical hypertrophy: establishing cause and toxicological significance
    Philip W Harvey
    Toxicology Department, Covance Laboratories, Otley Road, Harrogate, North Yorkshire HG31PY, UK
    J Appl Toxicol 30:617-26. 2010
  2. ncbi Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific
    Philip W Harvey
    Covance Laboratories, Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK
    J Appl Toxicol 32:1-9. 2012
  3. ncbi Adverse effects of prolactin in rodents and humans: breast and prostate cancer
    Philip W Harvey
    Department of Toxicology, Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire, UK
    J Psychopharmacol 22:20-7. 2008
  4. ncbi Adrenal toxicology: a strategy for assessment of functional toxicity to the adrenal cortex and steroidogenesis
    Philip W Harvey
    Covance Laboratories UK Ltd, Toxicology Department, Otley Road, Harrogate, North Yorkshire, UK HG3 1PY
    J Appl Toxicol 27:103-15. 2007
  5. ncbi Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer
    P W Harvey
    Department of Toxicology, Covance Laboratories Ltd, Harrogate, North Yorkshire, UK
    Hum Exp Toxicol 25:395-404. 2006
  6. ncbi Regulation of endocrine-disrupting chemicals: critical overview and deficiencies in toxicology and risk assessment for human health
    Philip W Harvey
    Toxicology Department, Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
    Best Pract Res Clin Endocrinol Metab 20:145-65. 2006
  7. ncbi Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments
    Philip W Harvey
    Department of Toxicology, Covance Laboratories, Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
    J Appl Toxicol 25:179-83. 2005
  8. ncbi Endocrine disrupters and human health: could oestrogenic chemicals in body care cosmetics adversely affect breast cancer incidence in women?
    Philip W Harvey
    Department of Toxicology, Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
    J Appl Toxicol 24:167-76. 2004
  9. ncbi The adrenal cortex and steroidogenesis as cellular and molecular targets for toxicity: critical omissions from regulatory endocrine disrupter screening strategies for human health?
    Philip W Harvey
    Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
    J Appl Toxicol 23:81-7. 2003
  10. ncbi Significance of the detection of esters of p-hydroxybenzoic acid (parabens) in human breast tumours
    Philip W Harvey
    J Appl Toxicol 24:1-4. 2004

Detail Information

Publications15

  1. ncbi Adrenocortical hypertrophy: establishing cause and toxicological significance
    Philip W Harvey
    Toxicology Department, Covance Laboratories, Otley Road, Harrogate, North Yorkshire HG31PY, UK
    J Appl Toxicol 30:617-26. 2010
    ....
  2. ncbi Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific
    Philip W Harvey
    Covance Laboratories, Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK
    J Appl Toxicol 32:1-9. 2012
    ..Toxicologists and regulators need to consider this in carcinogenicity risk assessments...
  3. ncbi Adverse effects of prolactin in rodents and humans: breast and prostate cancer
    Philip W Harvey
    Department of Toxicology, Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire, UK
    J Psychopharmacol 22:20-7. 2008
    ..More evidence is required concerning prostate cancer risk but molecular biology indicates that prolactin also induces prostate cell proliferation and inhibits apoptosis, which are similar to the responses observed in breast cancer cells...
  4. ncbi Adrenal toxicology: a strategy for assessment of functional toxicity to the adrenal cortex and steroidogenesis
    Philip W Harvey
    Covance Laboratories UK Ltd, Toxicology Department, Otley Road, Harrogate, North Yorkshire, UK HG3 1PY
    J Appl Toxicol 27:103-15. 2007
    ....
  5. ncbi Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer
    P W Harvey
    Department of Toxicology, Covance Laboratories Ltd, Harrogate, North Yorkshire, UK
    Hum Exp Toxicol 25:395-404. 2006
    ..Alteration of prolactin level is also a novel mechanism that requires consideration in endocrine disruption research, since both endogenous oestrogens and also xenoestrogens stimulate prolactin secretion or affect prolactin receptors...
  6. ncbi Regulation of endocrine-disrupting chemicals: critical overview and deficiencies in toxicology and risk assessment for human health
    Philip W Harvey
    Toxicology Department, Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
    Best Pract Res Clin Endocrinol Metab 20:145-65. 2006
    ....
  7. ncbi Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments
    Philip W Harvey
    Department of Toxicology, Covance Laboratories, Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
    J Appl Toxicol 25:179-83. 2005
    ..Drugs and chemicals causing rodent prolactin-induced mammary carcinogenesis may therefore pose a risk to humans via the same mechanism if exposures also increase prolactin secretion in humans...
  8. ncbi Endocrine disrupters and human health: could oestrogenic chemicals in body care cosmetics adversely affect breast cancer incidence in women?
    Philip W Harvey
    Department of Toxicology, Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
    J Appl Toxicol 24:167-76. 2004
    ..The exposure issues are clear and the exposed population is large, and these factors should provide the necessary impetus to investigate this potential issue of public health...
  9. ncbi The adrenal cortex and steroidogenesis as cellular and molecular targets for toxicity: critical omissions from regulatory endocrine disrupter screening strategies for human health?
    Philip W Harvey
    Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
    J Appl Toxicol 23:81-7. 2003
    ....
  10. ncbi Significance of the detection of esters of p-hydroxybenzoic acid (parabens) in human breast tumours
    Philip W Harvey
    J Appl Toxicol 24:1-4. 2004
    ..the toxicology of these compounds and 4). the limitations of the existing toxicology database and the need to consider data that is appropriate to human exposures...
  11. ncbi Antipsychotics and hyperprolactinaemia: clinical recommendations
    Robert C Peveler
    University of Southampton, Royal South Hants Hospital, Southampton, UK
    J Psychopharmacol 22:98-103. 2008
    ..We hope it will add to the debate about this topic...
  12. ncbi Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks
    Philippa D Darbre
    School of Biological Sciences, The University of Reading, Reading RG6 6AJ, UK
    J Appl Toxicol 28:561-78. 2008
    ....
  13. ncbi Parabens, oestrogenicity, underarm cosmetics and breast cancer: a perspective on a hypothesis
    Philip W Harvey
    J Appl Toxicol 23:285-8. 2003
    ..The role of oestrogens in breast cancer, however, is undisputed...
  14. ncbi Approaches to the assessment of toxicity data with endpoints related to endocrine disruption
    Philip W Harvey
    National Centre for Environmental Toxicology, WRc NSF Ltd, Henley Road, Medmenham, Marlow, Bucks SL7 2HD, UK
    J Appl Toxicol 22:241-7. 2002
    ....
  15. ncbi Comment on developmental toxicity evaluation of butylparaben in Sprague-Dawley rats
    Philip W Harvey
    Birth Defects Res B Dev Reprod Toxicol 74:114-5; author reply 116-7. 2005